Expression and role of phosphodiesterase 5 in human malignant melanoma cell line

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 355-358

  Murata, Taku ^a   Shimizu, Kasumi ^a   Watanabe, Yoshihiro ^a   Morita, Hiroshi ^a   Sekida, Motoko ^a   Tagawa, Toshiro ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Human malignant melanoma; Phosphodiesterase; Phosphodiesterase 5

Indexed keywords

MESSENGER RNA; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE 5A1; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOMA; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

BLOTTING, WESTERN; CELL PROLIFERATION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HUMANS; MELANOMA; PHOSPHODIESTERASE INHIBITORS; PURINONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77950533215     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Manganiello V: Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized. Mol Pharmacol 63: 1209-1211, 2003.
2. Francis SH, Turko IV and Corbin JD: Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65: 1-52, 2001.
3. Manganiello V: Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction. Int J Impot Res 16: 1-3, 2004.
4. Beavo JA, Houslay MD and Francis SH: Cyclic nucleotide phosphodiesterases Superfamily. In: Cyclic Nucleotide Phosphodiesterases in Health and Disease. Beavo JA, Francis SH and Houslay MD (eds.). Boca Raton, CRC Press, pp. 3-17, 2007.
5. Francis SH, Zoraghi R, Kotera J, Ke H, Bessay EP, Blount MA and Corbin JD: Phosphodiesterase 5: Molecular characteristics relating to structure, function, and regulation. In: Cyclic Nucleotide Phosphodiesterases in Health and Disease. Beavo JA, Francis SH and Houslay MD (eds.). Boca Raton, CRC Press, pp. 131-164, 2007.
6. Kamei T, Inui M, Nakamura S, Okumura K, Goto A and Tagawa T: Interferon-γ and anti-Fas antibody-induced apoptosis in human melanoma cell lines and its relationship to bcl-2 cleavage and bak expression. Melanoma Res 13: 153-159, 2003.
7. Degerman E, Moos MJr, Rascón A, Vasta V, Meacci E, Smith CJ, Lindgren S, Andersson KE, Beitrage P and Manganiello V: Single-step affinity purification, partial structure and properties of human platelet cGMP inhibited cAMP phosphodiesterase. Biochim Biophys Acta 1205: 189-198, 1994.
8. Drees M, Zimmermann R and Eisenbrand G: 3′,5′-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 53: 3058-3061, 1993.
9. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D and Pamukcu R: Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 60: 3338-3342, 2000.
10. Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, Fetter J R, Gresh WE Jr, Klein-Szanto AJ, Farnell DR, Eto I and Grubbs CJ: Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 61: 3961-3968, 2001.
11. Zhu B, Vemavarapu L, Thompson WJ and Strada SJ: Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94: 336-350, 2005.
12. Giordano D, Giorgi M, Sette C, Biagioni S and Augusti-Tocco G: cAMP-dependent induction of PDE5 expression in murine neuroblastoma cell differentiation. FEBS Lett 446: 218-222, 1999.
13. Sopory S, Kaur T and Visweswariah SS: The cGMP-binding, cGMP-specific phosphodiesterase (PDE5): intestinal cell expression, regulation and role in fluid secretion. Cell Signal 16: 681-692, 2004.